SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jack w garnes jr. who wrote (11218)7/11/1998 7:24:00 AM
From: al  Read Replies (2) of 23519
 
dailynews.yahoo.com

Yahoo! News
AP Headlines

Friday July 10 1:34 PM EDT

Critics Question FDA Safety Net

LAURAN NEERGAARD AP Medical Writer

WASHINGTON (AP) - Almost as many prescription drugs were yanked off the U.S. market in
the past 10 months as were banned in the entire previous decade, a spate that has critics questioning
if the Food and Drug Administration's safety nets are breaking down.

A senator has persuaded Congress' General Accounting Office to investigate whether the FDA -
under political pressure to speed approvals - is doing enough to safeguard against risky medicines,
or is passing drugs that once would have been held up for further study. One longtime FDA
pharmacologist told The Associated Press that she just left the agency in frustration with pressure to
skim over safety concerns.

The message was that ''one should be approving things, not questioning problems that arise, and ...
give the drug company the benefit of the doubt,'' said Elizabeth Barbehenn, who spent 13 years at
FDA monitoring the safety of certain experimental drugs.

''The red flag is up,'' said consumer advocate Dr. Sidney Wolfe of Public Citizen, who noted
experts had questioned some of the five recently banned medicines before they were ever sold.
''Whoever is responsible for creating the attitude at the FDA that they have to approve drugs even
with serious safety concerns is starting to see the bloody results.''

Dr. Michael Friedman, FDA's acting commissioner, vehemently denies that outside pressure
influences drug-safety decisions.

''What drives the agency is not political or commercial or any other interest short of scientific,'' said
Friedman. ''It is not a responsible position ... to suggest the agency would ... do anything less than
our very best to make public health decisions.''

The FDA appropriately approved the later-banned drugs because the full scope of side effects did
not show up at first - and the system worked by catching them as soon as they did appear,
Friedman said.

Five drugs have been pulled off the market since September: The painkiller Duract for causing liver
failure, including four deaths and eight liver transplants; the blood pressure drug Posicor, after 400
injuries and 24 deaths when it interacted dangerously with other medications; the diet drugs
fenfluramine and Redux for damaging hearts; and the antihistamine Seldane, which interacted lethally
with a long list of other drugs.

In the previous 10 years, the FDA had banned just six other drugs.

The FDA performs a complex balancing act: Getting the promising new drugs to desperately ill
patients quickly, at the same time hunting the often subtle clues that signal which drugs will cause
dangerous side effects.

Drugs are approved based on studies in a few hundred to a few thousand carefully chosen patients.
That means rare problems may not emerge until tens of thousands of patients, or sicker ones, take
them.

Over the past three years, Congress intensely pressured the once-backlogged FDA to speed
approvals. Critics even accused FDA of killing patients by delaying potentially lifesaving therapies.

Attempts to force a drastic speedup ultimately failed. Still, by charging new fees to drug makers,
FDA hired hundreds more reviewers and approved a record 92 unique new drugs in 1996 and
1997, up from 50 the previous two years.

Faster approval of lifesaving therapies is good, Wolfe said - but just 20 percent of FDA-approved
products are medical breakthroughs.

Most instead are ''me-too'' drugs like the just-banned Duract and Posicor. Wolfe lists at least 18
similar painkillers and 30 blood-pressure alternatives, questioning why the two were approved last
year. The FDA knew that Duract, for example, caused serious liver damage if taken for longer than
10 days.

And there's a separate problem: How to inform doctors of the side effects that come with every
drug.

Some 2 million Americans are hospitalized annually for side effects, and 100,000 die, Thomas J.
Moore, a researcher at George Washington University, reported this spring.

The FDA has to upgrade safety warnings on more than 20 drugs every month.

But doctors aren't required to report side effects to FDA so it can warn the public, and many don't.
The agency has only about 80 employees to monitor more than 3,000 prescription drugs, but is
working to improve surveillance, Friedman said.

Nor can the FDA force doctors to heed warnings. Duract, the painkiller, had to be banned because
doctors ignored FDA's warning not to prescribe it for longer than 10 days, Friedman said. ''If these
products were used as prescribed, many of them would still be on the market.''

Sen. Edward Kennedy, D-Mass., asked the GAO to quickly investigate how well the FDA handles
drug safety and side effects. Republicans, too, are making inquiries, but agree with Friedman that
the drug bans actually may mean the system is working by detecting trouble.

There's no easy answer, because every drug approved is ultimately a judgment call, stressed
Moore. He wants Congress to establish a scientific panel that judges how the FDA handles drug
controversies, much as the National Transportation Safety Board investigates plane crashes.

''How safe does a drug have to be? There is no simple answer,'' Moore said. ''It is a question of
getting the right balance, of learning from our mistakes, which is not happening now.''
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext